

-continued

---

Phe Pro His Phe Asp Leu Ser His Gly Ser Ala Gln Val  
1 5 10

<210> SEQ ID NO 5  
<211> LENGTH: 4  
<212> TYPE: PRT  
<213> ORGANISM: Artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: sequence is synthesized  
<220> FEATURE:  
<221> NAME/KEY: ACETYLATION  
<222> LOCATION: (1)..(1)  
<223> OTHER INFORMATION: N-acetyl

<400> SEQUENCE: 5

Ser Asp Lys Pro  
1

<210> SEQ ID NO 6  
<211> LENGTH: 15  
<212> TYPE: PRT  
<213> ORGANISM: Artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: sequence is synthesized

<400> SEQUENCE: 6

His Phe Asp Leu Ser His Gly Ser Ala Gln Val Ser Asp Lys Pro  
1 5 10 15

<210> SEQ ID NO 7  
<211> LENGTH: 14  
<212> TYPE: PRT  
<213> ORGANISM: Artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: sequence is synthesized

<400> SEQUENCE: 7

Phe Asp Leu Ser His Gly Ser Ala Gln Val Ser Asp Lys Pro  
1 5 10

---

40

What is claimed is:

1. An oligopeptide having the sequence Phe-Xaa-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 1), wherein Xaa is Pro or Ala.

2. The oligopeptide of claim 1 having the sequence Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 2).

3. The oligopeptide of claim 1 having the sequence Phe-Ala-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 3).

4. A pharmaceutical composition comprising a compound (SEQ ID NO: 1) for mobilizing stem cells from bone marrow of a subject.

5. A method of mobilizing stem cells from bone marrow of a subject, comprising administering to the subject an amount of compound (SEQ ID NO: 1) effective to mobilize the stem cells.

6. The method of claim 5, wherein the subject is a human and the amount of (SEQ ID NO: 1) is from 100 micrograms to 10 milligrams per administration, administered from 1 time per week to 3 times per day.

7. A method for treating a subject in need of one or more of preservation, repair, or regeneration of bodily tissue, or revascularization, comprising the method of claim 5, thereby promoting the one or more of preservation, repair, or regeneration of bodily tissue or regeneration in the subject.

8. A method for treating a subject in need of one or more of preservation, repair, or regeneration of bodily tissue, or revascularization, comprising the method of claim 6, thereby promoting the one or more of preservation, repair, or regeneration of bodily tissue or regeneration in the subject.

9. The method of claim 7, wherein the tissue that is preserved, repaired or regenerated is pancreatic tissue.

10. A method of treating diabetes comprising the method of claim 9.

11. The method of claim 8, wherein the tissue that is preserved, repaired or regenerated is pancreatic tissue.

12. A method for treating diabetes comprising the method of claim 11.

13. The method of claim 7, wherein the tissue that is preserved, repaired, or regenerated is dermal tissue.

14. A method for treating a dermal wound, comprising the method of claim 13.

15. The method of claim 8, wherein the tissue that is preserved, repaired, or regenerated is dermal tissue.

16. A method of treating a dermal wound, comprising the method of claim 15.

17. The method according to claim 5, wherein the compound has the sequence Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 2).